Division of Pediatric Critical Care Medicine, Department of Pediatrics, Rainbow Babies and Children's Hospital, Cleveland, OH.
Division of Neonatology, Department of Pediatrics, Rainbow Babies and Children's Hospital, Cleveland, OH.
Pediatr Crit Care Med. 2017 Dec;18(12):e606-e614. doi: 10.1097/PCC.0000000000001351.
Critically ill children with bronchiolitis may require neuropharmacologic medications and support for neuro-functional sequelae, but current practices are not well described. We aimed to describe recent trends in neuropharmacology and utilization of neuro-rehabilitation resources in mechanically ventilated children with bronchiolitis.
Analysis of the multicenter Pediatric Health Information System database.
Forty-seven U.S. children's hospitals.
PICU patients less than 2 years old with bronchiolitis undergoing mechanical ventilation between 2006 and 2015.
None. Annual rates of utilization of neuropharmacologic medications (sedatives, analgesics, etc) and of neuro-rehabilitation services (physical therapy, neurologic consultation, etc) over the 10-year study period were compared.
Neuropharmacologic medications prescribed on greater than or equal to 2 days were extracted. Utilization of MRI of the brain, neurologic consultation, swallow evaluation, occupational therapy, and physical therapy was also extracted. Among 12,508 subjects, the median age was 2.8 months, ~50% had comorbid conditions, and the median duration of mechanical ventilation was 7 days. The percentage of children prescribed greater than or equal to five drugs/drug classes increased over the study period from 36.5% to 55.8% (p < 0.001). There were significant increases over time in utilization of 10 of the 15 individual drugs/drug classes analyzed. More than half of subjects (6,294 [50.3%]) received at least one service that evaluates/treats neurologic morbidity. There were significant increases in the use of greater than or equal to one service (36.3% in 2006 to 59.6% in 2015; p < 0.001) and in the use of greater than or equal to two services (20.8% to 34.8%; p < 0.001). Utilization of each of the five individual resources increased significantly during the study period, but use of vasoactive medications and mortality did not.
Prescription of neuropharmacologic agents increased over time using metrics of both overall drug burden and specific drug usage. Concurrently, the utilization of services that evaluate and/or treat neurologic morbidity was common and also increased over time.
患有细支气管炎的危重病儿童可能需要神经药理学药物和神经功能后遗症的支持,但目前的治疗方法尚不清楚。我们旨在描述机械通气的细支气管炎儿童中神经药理学和神经康复资源利用的最新趋势。
对多中心儿科健康信息系统数据库进行分析。
美国 47 家儿童医院。
2006 年至 2015 年期间,在儿科重症监护病房接受机械通气治疗且年龄小于 2 岁的毛细支气管炎患者。
无。在 10 年的研究期间,比较了神经药理学药物(镇静剂、镇痛药等)和神经康复服务(物理治疗、神经科咨询等)的年度使用率。
提取了使用大于或等于 2 天的药物。还提取了脑磁共振成像、神经科咨询、吞咽评估、职业治疗和物理治疗的使用情况。在 12508 名患者中,中位年龄为 2.8 个月,约 50%有合并症,机械通气的中位时间为 7 天。在研究期间,使用大于或等于 5 种药物/药物类别的患儿比例从 36.5%增加到 55.8%(p<0.001)。分析的 15 种药物/药物类别的 10 种药物的使用量随时间显著增加。超过一半的患者(6294 例[50.3%])接受了至少一种评估/治疗神经系统发病率的服务。大于或等于一种服务的使用(2006 年为 36.3%,2015 年为 59.6%;p<0.001)和大于或等于两种服务的使用(20.8%至 34.8%;p<0.001)均显著增加。在研究期间,五种单独资源中的每一种的利用率都显著增加,但血管活性药物的使用和死亡率并没有增加。
随着时间的推移,使用总体药物负担和特定药物使用的指标,神经药理学药物的处方量增加。同时,评估和/或治疗神经系统发病率的服务的利用率也很高,并且随着时间的推移而增加。